|
covid-19 |
67 |
|
covid-19 vaccine |
39 |
|
sars-cov-2 |
38 |
|
chinese |
33 |
|
vaccine safety |
29 |
|
bnt162b2 |
28 |
|
children |
28 |
|
coronavac |
28 |
|
covid-19 vaccines |
20 |
|
atrial fibrillation |
19 |
|
inactivated vaccine |
18 |
|
self-controlled case series |
18 |
|
heart failure |
17 |
|
child psychosocial problems |
16 |
|
coronavirus |
16 |
|
healthcare workers |
16 |
|
home confinement |
16 |
|
hospital policies |
16 |
|
perceived stress |
16 |
|
psychological wellbeing |
16 |
|
school closure |
16 |
|
epidemiology |
15 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
cancer |
13 |
|
cytokines |
13 |
|
immunoglobulin |
13 |
|
lymphocyte subsets |
13 |
|
sars |
13 |
|
adverse events |
12 |
|
false positive |
12 |
|
innate immunity |
12 |
|
kawasaki disease |
12 |
|
serology |
12 |
|
tuberculosis |
12 |
|
omicron |
11 |
|
paediatrics |
11 |
|
public health |
11 |
|
safety |
11 |
|
statistics & research methods |
11 |
|
all-cause pneumonia |
10 |
|
autoimmune disorders |
10 |
|
delirium |
10 |
|
dementia |
10 |
|
health equity |
10 |
|
herd immunity |
10 |
|
incident cvd |
10 |
|
interrupted time series analysis |
10 |
|
ischemic stroke |
10 |
|
long covid |
10 |
|
major adverse cardiovascular events |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population-based electronic health records |
10 |
|
post-covid cvd |
10 |
|
sex difference |
10 |
|
adverse events of special interest (aesi) |
9 |
|
age-stratified |
9 |
|
asia |
9 |
|
cardiovascular complications |
9 |
|
diabetes |
9 |
|
infection |
9 |
|
microvascular complications |
9 |
|
molnupiravir |
9 |
|
nirmatrelvir-ritonavir |
9 |
|
pediatrics |
9 |
|
pharmacovigilance |
9 |
|
travel history |
9 |
|
vaccine |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
abdominal pain |
8 |
|
adverse events of special interest |
8 |
|
diarrhoea |
8 |
|
drug regulatory |
8 |
|
mrna vaccine |
8 |
|
myocarditis |
8 |
|
orphan drug policy |
8 |
|
paediatric gastroenterology |
8 |
|
pediatric population |
8 |
|
pericarditis |
8 |
|
rare diseases |
8 |
|
treatment access |
8 |
|
vaccine effectiveness |
8 |
|
cervical screening |
7 |
|
dialysis patients |
7 |
|
hpv vaccination |
7 |
|
peritoneal dialysis |
7 |
|
renal replacement therapy |
7 |
|
sexual behaviour |
7 |
|
burden of disease |
6 |
|
elderly care |
6 |
|
healthcare resource |
6 |
|
pneumonia admission |
6 |
|
population aging |
6 |
|
warfarin |
6 |
|
anticoagulant |
5 |
|
bdmards |
5 |
|
bleeding |
5 |
|
cardiovascular safety of biologics |
5 |
|
dabigatran |
5 |
|
enalapril |
5 |
|
gastrointestinal bleeding |
5 |
|
jak inhibitors |
5 |
|
medication safety |
5 |
|
mortality |
5 |
|
orphan drug designation |
5 |
|
pharmacoepidemiolgy |
5 |
|
postmarketing surveillance |
5 |
|
readmission |
5 |
|
real-world observational study |
5 |
|
real‐life |
5 |
|
rheumatoid arthritis |
5 |
|
risk–benefit trade-off |
5 |
|
rivaroxaban |
5 |
|
sacubitril/valsartan |
5 |
|
anticoagulant agent |
4 |
|
antiplatelet |
4 |
|
cardio-oncology |
4 |
|
pharmacoepidemiology |
4 |
|
prevention |
4 |
|
statin |
4 |
|
anticoagulation |
3 |
|
anticoagulation therapy |
3 |
|
antirheumatic agents |
3 |
|
arthritis |
3 |
|
cost-effectiveness analysis |
3 |
|
drug costs |
3 |
|
health expenditures |
3 |
|
healthcare cost |
3 |
|
hong kong |
3 |
|
janus kinases |
3 |
|
major depressive disorder |
3 |
|
markov model |
3 |
|
public mental health |
3 |
|
rheumatoid |
3 |
|
social epidemiology |
3 |
|
stroke prophylaxis |
3 |
|
amfetamine |
2 |
|
biologic |
2 |
|
cost-effectiveness |
2 |
|
fc-fusion protein |
2 |
|
mab |
2 |
|
methamfetamine |
2 |
|
naltrexone |
2 |
|
pcv13 |
2 |
|
pharmacoeconomics |
2 |
|
pneumonia |
2 |
|
ppsv23 |
2 |
|
tolerability |
2 |
|
high-throughput screening (hts) |
1 |
|
osteoporosis |
1 |
|
osteoprotegerin (opg) |
1 |
|
receptor activator of nf--κb ligand (rankl) |
1 |
